CING Cingulate Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1862150 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-30.3%
TTM EPS YoY22.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-240.8%
ROA-151.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets26.2%
Debt / equity0.00x
Current ratio3.90x
Interest coverage-25.09x
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-27.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $9.77M | $9.45M | $15.49M | $9.00M | $8.41M |
| SG&A expense | $10.16M | $6.20M | $7.27M | $8.51M | $12.27M |
| Operating income | -$19.94M | -$15.64M | -$22.76M | -$17.50M | -$20.68M |
| Interest expense | $901,325 | $25,354 | $790,000 | $292,339 | $33,407 |
| Pretax income | -$22.45M | -$16.56M | -$23.53M | -$17.68M | -$20.71M |
| Net income | -$22.45M | -$16.56M | -$23.53M | -$17.68M | -$20.71M |
| EBITDA | -$19.40M | -$14.99M | -$22.18M | -$17.11M | -$19.97M |
| EPS (basic) | -4.44 | -10.86 | -311.99 | -29.35 | -2.79 |
| EPS (diluted) | -4.44 | -10.86 | -311.99 | -29.35 | -2.79 |
| Weighted avg. shares (diluted) | 5.06M | 1.52M | 75,435 | 602,340 | 7.41M |
| Banking | |||||
| Net interest income | -$1.36M | $99,236 | — | — | — |
| Balance sheet | |||||
| Cash & equivalents | $10.95M | $12.21M | $52,416 | $5.36M | $16.49M |
| Short-term investments | — | — | — | — | $933 |
| Receivables | — | — | $14,622 | — | — |
| Current assets | $12.01M | $12.66M | $578,594 | $7.87M | $18.88M |
| PP&E, net | $1.73M | $2.10M | $2.55M | $2.90M | $3.15M |
| Total assets | $15.07M | $14.86M | $3.49M | $11.41M | $22.89M |
| Current liabilities | $10.31M | $4.97M | $10.23M | $7.01M | $1.18M |
| Total liabilities | $12.56M | $7.41M | $10.36M | $7.52M | $2.04M |
| Shareholders' equity | $2.51M | $7.46M | -$6.87M | $3.88M | $20.84M |
| Shares outstanding | 7.25M | 3.40M | 97,293 | 602,640 | 11.31M |
| Cash flow statement | |||||
| Operating cash flow | -$17.25M | -$18.45M | -$15.03M | -$15.88M | -$10.43M |
| Capital expenditure | $162,138 | $211,800 | $224,096 | $153,420 | $814,736 |
| Free cash flow | -$17.41M | -$18.66M | -$15.26M | -$16.04M | -$11.25M |
| Investing cash flow | -$162,138 | -$211,800 | -$224,096 | -$152,652 | -$814,736 |
| Financing cash flow | $16.15M | $30.82M | $9.95M | $4.90M | $26.54M |
| Depreciation & amortization | $540,894 | $653,090 | $582,918 | $394,011 | $708,317 |
| Stock-based compensation | $1.52M | $995,484 | $812,670 | $800,796 | $43,835 |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.